After the Rebranding and Cost Increase, the Use of Vasopressin Continues to Increase Yearly Especially in Case of Acute Kidney Injury With Septic Shock: Is There Recent Data Justifying It?

Honoré, Patrick;Redant, Sebastien;Djimafo, Pharan;Blackman, Sydney;Attou, Rachid;et.al.
(2023) Critical Care Medicine — Vol. 51, n° 2, p. e68-e69 (2023)

Files

HonorePCritCareMed2023.pdf
  • Open Access
  • Adobe PDF
  • 481.33 KB
Download

Details

Authors
  • Honoré, PatrickUCLouvain
    Author
  • Redant, Sebastien
    Author
  • Djimafo, Pharan
    Author
  • Blackman, Sydney
    Author
  • Attou, Rachid
    Author
Show more
Abstract
(en) Sacha et al showed that vasopressin was utilized in 42.6% of acute kidney injury (AKI) before and increased to 54.6 % after rebranding, which seems to be high despite the cost increase. We reviewed potentialjustifications for the vasopressin increased use in AKI during septic shock (SS) after rebranding. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Honoré, P., Redant, S., Djimafo, P., Blackman, S., Bousbiat, I., Perriens, E., Preseau, T., Cismas, B. V., Kaefer, K., Gutierrez, L. B., Anane, S., Gallerani, A., & Attou, R. (2023). After the Rebranding and Cost Increase, the Use of Vasopressin Continues to Increase Yearly Especially in Case of Acute Kidney Injury With Septic Shock: Is There Recent Data Justifying It? Critical Care Medicine, 51(2), e68-e69. https://doi.org/10.1097/CCM.0000000000005725 (Original work published 2023)